Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment

Biomarker Research

Lesang Shen¹  Chao Ni¹  Jingxin Jiang¹  Zhigang Chen¹  Wuzhen Chen¹  Leyi Zhang²  Jun Pan²  Zhigang Zhang² 

[1]Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine

[2]Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province

关键词: Antiangiogenic therapy;    Immunotherapy;    Breast cancer;    Tumor microenvironment (TME);   

DOI  :  10.1186/s40364-021-00312-w

来源: DOAJ

【 摘 要 】

Abstract Tumor angiogenesis induces local hypoxia and recruits immunosuppressive cells, whereas hypoxia subsequently promotes tumor angiogenesis. Immunotherapy efficacy depends on the accumulation and activity of tumor-infiltrating immune cells (TIICs). Antangiogenic therapy could improve local perfusion, relieve tumor microenvironment (TME) hypoxia, and reverse the immunosuppressive state. Combining antiangiogenic therapy with immunotherapy might represent a promising option for the treatment of breast cancer. This article discusses the immunosuppressive characteristics of the breast cancer TME and outlines the interaction between the tumor vasculature and the immune system. Combining antiangiogenic therapy with immunotherapy could interrupt abnormal tumor vasculature-immunosuppression crosstalk, increase effector immune cell infiltration, improve immunotherapy effectiveness, and reduce the risk of immune-related adverse events. In addition, we summarize the preclinical research and ongoing clinical research related to the combination of antiangiogenic therapy with immunotherapy, discuss the underlying mechanisms, and provide a view for future developments. The combination of antiangiogenic therapy and immunotherapy could be a potential therapeutic strategy for treatment of breast cancer to promote tumor vasculature normalization and increase the efficiency of immunotherapy.

【 授权许可】

Unknown